MedTrace Logo

A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

NCT01499446 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 669

Last updated 2016-09-15

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and safety of GW685698X 100mcg once daily either in the morning or the evening and GW685698X 250mcg administered once daily in the evening via DISKHALER for 28 days in subjects with persistent bronchial asthma.

Conditions

Interventions

DRUG

GW685698X (fluticasone furoate) 100mcg Morning

GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days

DRUG

GW685698X (fluticasone furoate) 100mcg Evening

GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days

DRUG

GW685698X (fluticasone furoate) 250mcg Evening

GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days

DRUG

Placebo

Placebo inhaled twice daily (morning and evening) for 28 days

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2004-03-31
Completion
2004-03-31

Countries

  • Brazil
  • Bulgaria
  • Chile
  • Croatia
  • Estonia
  • Germany
  • Greece
  • Hungary
  • Italy
  • Mexico
  • Romania
  • Russia
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01499446 on ClinicalTrials.gov